It is estimated that 6-7 global innovative drug products will be in global clinical phase I-III, and the capital market IPO will be launched

MT1002 completed US clinical phase IIa
MT1001 in Chinese clinical phase IIa
MT2004 completed US clinical phase I
MT1009 applied for Sino US clinical phase I
MT1013 applied for China clinical phase I
Start round A financing

MT1002 starts the American clinical phase II;
MT2004 entered American Phase I clinic;
MT1001 starts the Chinese clinical phase II;
Completed a total of 115 million yuan of Pre-A round financing of Northern Lights Venture Capital, Tianshili Holding, Detong Capital, Shaanxi Investment Group, etc

The global Class 1 innovative drug MT1002 has completed the US clinical application;
MT1001 completed clinical Ib experiment;
MT-ASNT China Clinical Review and Approval

MT1001 completed clinical phase Ia experiment; Subsidiary Altay Pharmaceutical obtained financing of 20 million yuan

Once again, it won the special support of national major new drug innovation, and AXBN obtained the clinical approval document

New drug MT1001 obtained clinical approval

Transfer of innovative drug variety MT1001 to obtain 220 million milestone payments, and support rapid research and development of other products

Won a number of national major new drug development special grants

The company was established in 2007 to carry out basic research